Show featured John Glushko, author of “Anatomy of a Stock Market Killing”. We also interviewed Terry Howlett, CEO of Skinvisible Pharmaceuticals (SKVI), a research and development company that licenses its proprietary formulations made with Invisicare®. This patented polymer delivery system offers life cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. All Invisicare® patents are owned by Skinvisible.
Skinvisible recently announced that its licensee, Women’s Choice Pharmaceuticals LLC, launched ProCort(R), Skinvisible’s first prescription product in the United States. ProCort(R) is a topical treatment for hemorrhoids formulated with Skinvisible’s patented polymer delivery system Invisicare(R). Invisicare enhances the delivery of active ingredients by controlling the release and provides superior binding properties — Read Research Report, Watch Webcast or Hear Audio